Chronic hepatitis B infection is one of the major etiological causes of liver failure, cirrhosis, and hepatocellular carcinoma (HCC) worldwide. This condition cannot be completely cured by currently available drugs due to the persistent existence of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA), the bona fide transcription template for HBV RNAs, in infected hepatocytes. Because quantifying cccDNA per se requires an invasive procedure, serum biomarkers reflecting intrahepatic cccDNA activity are warranted. Recently, a growing body of research suggests that the circulating HBV RNA may serve as a serum biomarker for HBV infection, treatment, and prognosis. In order to delineate the molecular and clinical characteristics of serum HBV RNA, we systematically reviewed the available literature on serum HBV RNA dating back to the early 1990s. In this review, we summarize the reported serum HBV RNA quantification methods and discuss the potential HBV RNA species in patient serum. We also compare the reported correlations of serum HBV RNA with other serological markers, including HBV DNA, hepatitis B surface antigen, e antigen, and core-related antigen, as well as their correlations with intrahepatic cccDNA, to assess their potential in clinical applications. Future directions for serum HBV RNA research are also discussed. (Hepatology 2019;69:1816-1827).
C urrently, nucleos(t)ide analogues (NAs) and PEGylated interferon (peg-IFN) are being used to treat patients with chronic hepatitis B (CHB), leading to suppression of hepatitis B virus (HBV) replication, improved histology, reversed histologic cirrhosis, and reduced risk of hepatocellular carcinoma (HCC).
(1) However, HBV infection cannot be completely eliminated due to the persistence of covalently closed circular DNA (cccDNA) in the nuclei of infected hepatocytes. (2) Due to the invasive nature of liver biopsy, it is impractical to quantify intrahepatic cccDNA as a routine diagnosis, making it necessary to develop noninvasive surrogate markers to monitor the quantity or activity of cccDNA. In the past, several serological markers, including HBV DNA, hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigens (HBcrAgs), have been shown to correlate with intrahepatic cccDNA. (3) (4) (5) Recently, serum HBV RNA has been considered as a new biomarker for cccDNA, (6) especially in virally suppressed patients with low detectable HBV DNA under NA therapy. In this review, we discuss the importance and scope of using serum HBV RNA as a potential biomarker for hepatitis B infection.
Serum HBV RNA in the Viral Life Cycle
The HBV life cycle starts with the engagement of virion particles to the hepatocyte receptor, termed "sodium taurocholate cotransporting polypeptide (NTCP)," and then the release of nucleocapsid containing viral relaxed circular DNA (rcDNA) into hepatocytes (Fig. 1) . The rcDNA is then transported to the nucleus, where it is converted into an episomal, nucleosome-decorated cccDNA minichromosome, through a series of mechanisms which are not yet fully understood. (7) The cccDNA serves as a transcription template for all viral transcripts, including the 3.5-kb precore RNA (pcRNA) and pregenomic RNA (pgRNA), the 2.4-kb and 2.1-kb surface mRNAs, and a 0.7-kb X mRNA. (8) The pgRNA is the template for both reverse transcription and translation of viral polymerase and core proteins. (9) The polymerase binds to the 5′-epsilon region of pgRNA, and together they are incorporated into the viral capsid. (10) Inside the capsid, the polymerase converts pgRNA into rcDNA through reverse transcription, followed by envelopment by HBV envelope proteins on the endoplasmic reticulum membrane for virion secretion through multivesicular bodies, (11) or reentry into the nucleus to replenish the cccDNA pool. In addition to rcDNA, HBV reverse transcription produces a minor viral DNA species, double-stranded linear DNA (dslDNA), which can be secreted as virion DNA and redirected into the nucleus to form cccDNA. (12) However, dslDNA is often randomly integrated into the host genome through nonhomologous end joining, (13) which may promote HCC development by inducing chromosomal instability, insertional mutagenesis of HBV genes, and HCCassociated host genes. (14) Unlike cccDNA, the integrated HBV genome does not produce functional pgRNA for viral DNA replication but may serve as an additional source for surface mRNA transcription and HBsAg expression. (15) According to the dogma of the HBV life cycle, only the mature, DNA-containing nucleocapsid interacts with viral surface proteins to undergo envelopment and virion secretion from hepatocytes. (16) Nonetheless, large amounts of HBV genome-free ("empty") virions have been found in patient blood and HBV cell culture fluid (17) (Fig. 1) . Ning et al. have reported a "single strand blocking" model to explain such selective HBV morphogenesis whereby the single-stranded nucleic acids within the viral capsids prevent HBV envelopment. (18) However, this model does not apply to several exceptions, such as the single-stranded DNA-containing virion of snow goose HBV (19) and the circulating HBV pgRNA-containing virus particles found in patient blood. (6, 20) Theoretically, serum HBV RNA comes from infected hepatocytes. Wang et al. have deep-sequenced HBV RNA in serum and the corresponding regions of paired viral RNA in the liver and found that the complexity and mean genetic distance between quasi-species of the two were comparable. (21) However, the mechanism underlying the release of HBV RNA into the circulation from aRtICle INFoRMatIoN:
infected hepatocytes remains unclear. Previous studies have demonstrated that HBV cell cultures noncytolytically secrete a large amount of nonenveloped ("naked") capsids which contain all types of HBV DNA replicative intermediates including pgRNA. (22) Thus, it is unclear whether the detected serum HBV RNA, or at least part of them, are from the "naked" capsid released into the bloodstream from HBVinfected hepatocytes in vivo or in vitro. (6) If the pgRNA-containing virions do exist, it would be interesting to know whether they are infectious and could establish a new round of infection. Wang et al. reported that HBV RNA virion-like particles produced by NA treatment are infection-deficient. (23) However, because NA-treated pgRNA virion is a dead-end due to the irreversible chain termination effect of NA, the above study does not rule out the potential infectivity of untreated pgRNA virion. Due to the similar protein composition and density between pgRNA and DNA virions, it is technically challenging to purify pgRNA virions for infectivity testing in cell cultures. Therefore, it remains debatable whether to incorporate HBV RNA virion-like particles into the canonical HBV replication cycle. (24) It is well known that encapsidated pgRNA is converted into rcDNA through reverse transcription, enveloped by viral surface proteins and secreted into the peripheral blood as Dane particles. (25) However, it is possible that a certain number of pgRNA-containing capsids may prematurely acquire envelope and get released into the peripheral blood. (24) However, the secretion of immature pgRNA virions and "naked" capsids may represent a host defense mechanism to combat HBV infection. Hence, further investigation is needed to accurately portray the biogenesis and function of HBV RNA virion-like particles in chronic HBV infection.
Serum HBV RNA Species and Measurement
HBV is known to be a blood-borne, enveloped, double-stranded DNA virus. In 1996, Kock et al. detected polyadenylated HBV RNA in the serum of CHB patients using rapid amplification of complementary DNA (cDNA) ends (RACE). (26) After extracting HBV RNA from patient serum, a special primer consisting of an oligo(dT) stretch and a unique artificial anchored sequence was used to generate cDNA. The cDNA was PCR-amplified with the upstream HBV-specific primer and downstream primers identical to the anchored sequence, thereby ensuring a high specificity for HBV polyA RNA amplification. (27) Thereafter, a similar method was used to detect serum HBV RNA in patients with HBV-related glomerulonephritis or CHB with or without successful treatment. (28) (29) (30) RACE-based real-time quantitative PCR using specific primers designed for reverse transcription, according to Kairat et al., (31) was later developed to selectively quantify serum 3′ full-length polyadenylated HBV RNA (flRNA) and 3′ internally-truncated polyadenylated HBV RNA (trRNA). The RACE-quantitative PCRbased flRNA quantification has been widely employed in recent studies. (32) (33) (34) (35) In addition to RACE-quantitative PCR, regular quantitative RT-PCR methods with HBV-specific primers targeting the X, C, or S region of the HBV genome were developed to quantify serum HBV RNA. (6, 20, (36) (37) (38) However, in order to avoid DNA contamination during quantitative RT-PCR, deoxyribonuclease I treatment of the nucleic acids extracted from serum is required. Alternatively, quantification of serum HBV RNA has been conducted through total HBV nucleic acid measurement by real-time quantitative RT-PCR without removing HBV DNA by deoxyribonuclease digestion, followed by subtracting HBV DNA copy numbers determined by quantitative PCR. (39) (40) (41) The QuantiGene assay developed by Lam et al. uses HBV-specific probes, designed to hybridize with the X open reading frame (ORF), to enable direct quantification of RNA without cDNA synthesis or PCR amplification. (42) Recently, Butler et al. developed an automated high-throughput assay to quantify serum HBV RNA, which was isolated using RNA selective extraction chemistry (Abbott mSample Preparation System), followed by a multiplex quantitative RT-PCR procedure for detecting amplicons of hepatitis B X and core region on the m2000 platform (Abbott Molecular). (43) To further evaluate the automated prototype assay performance, Butler et al. conducted a comparative testing of flRNA and found a good correlation between these two methods. All of the published methods for quantifying serum HBV RNA are summarized in Table 1 and Figure 2 for comparison. In earlier studies, the species and form of serum HBV RNA have not been rigorously characterized. Rokuhara et al. speculated that the serum HBV RNA (36) In 2015, Jansen et al. reported that HBV RNA is present in virions in CHB patients' plasma by immunoprecipitating hepatitis B core antigen (HBcAg) with anticore antibodies after treatment with Nonidet P-40 and dithiothreitol; however, they failed to detect HBV RNA after HBsAg immunoprecipitation. (20) In 2016, Wang et al. conducted a series of experiments in the HBV stable cell line HepAD38 and claimed that the supernatant HBV RNA is encapsidated pgRNA. (6) However, as mentioned, their study did not distinguish virions from "naked" capsids, both of which may contain pgRNA. Interestingly, "naked" capsids are commonly detected in the supernatant of HBV cell cultures but are barely detected in the blood of CHB patients, (44, 45) indicating a possible presence of RNA virion in patient sera. Therefore, more reliable assays and convincing evidence are needed to verify the existence of enveloped RNA-containing HBV particles.
As mentioned, HBV produces the 3.5-kb pcRNA and pgRNA, 2.4/2.1-kb surface mRNAs, and 0.7-kb X mRNA intracellularly, which share the same 3′-terminal sequences overlapping with X mRNA (Figures 1 and 2) . In order to determine the serum HBV RNA species, Wang et al. conducted quantitative The direct repeat sequence DR1 and DR2 are denoted on pgRNA; vertical red and black arrows pointing to pgRNA indicate the major 5′ splicing donor sites and 3′ splicing acceptor sites of pgRNA, respectively. Red lines underneath HBV mRNAs represent the PCR amplicon in the referenced studies (denoted with reference numbers in square brackets). Multiple PCR amplicons from the same reference are numbered. Primer information is provided in the embedded table, and additional information can be found in Table 1. Notes to table:   a The HBV-specific RT-primer in Wang et al. (6) is composed of an HBV-specific sequence and a unique anchored sequence at the 5′ end. The anchored sequence is used as the reverse primer in PCR cycles. The reverse transcription primer in van Bommel et al. (32) contains a 3′-terminal sequence complementary to the HBV flRNA or trRNA sequence adjacent to the polyA tail, a middle stretch of oligo(dT), and a 5′ artificial anchored sequence. The anchored sequence is the same as that of the reverse primer. The sequences of reverse primers in Jansen et al., (20) Wang et al., (21) Rokuhara et al., (36) Prakash et al., (38) and Wang et al. (52) are identical to those of the reverse transcription primers. Abbreviations: DR, direct repeat; FW, forward; gt, genotype; nt, nucleotide; RT, reverse transcription; RV, reverse.
RT-PCR assays to quantify serum total HBV RNA and 3.5-kb RNA separately and obtained similar copy numbers. They further conducted PCR with 3.5-kb HBV RNA-specific primers and pcRNA-specific primers and ruled out the presence of pcRNA in serum. (6) However, Prakash et al. performed supersensitive droplet digital PCR with similar primers as used by Wang et al. and detected a small amount of pcRNA in serum. (38) Nonetheless, although the discrepancy among different studies might be due to the variable specificity and/or sensitivity of different assays, the detected serum HBV RNA sequences appear to be predominantly derived from pgRNA. Then, a critical question that needs to be answered is whether the serum pgRNA is 3.5-kb genome length or not. Prakash et al. reported that serum HBV RNA is polyadenylated and of genomic length (38) ; however, the multiple-round PCR method used in their study might have selectively amplified the genomelength polyadenylated pgRNA but neglected the presence of polyA-free serum HBV RNA, which has been identified by Hacker et al. (30) Furthermore, Lam et al. detected both full-length HBV pgRNA (minor species) and the spliced variants (major species) in the supernatant of HBV-infected HepaRG cells treated with or without lamivudine, as well as in CHB patient sera. (42) Another study by Wang et al. reported that numerous short pgRNA species were detected by PCR and identified as pgRNA splicing variants and/or 3′-terminal truncations induced by NA treatment. (23) The NA-induced accumulation of 3′-truncated polyA-free pgRNA, catalyzed by the ribonuclease H activity of HBV polymerase, has also been demonstrated intracellularly. (46) Therefore, serum HBV RNA is likely a mixture of intact, spliced, and polyA-free pgRNA. Among polyadenylated serum HBV RNA species, the reported flRNA and trRNA species can be discriminated by the aforementioned 3′-RACE-quantitative PCR with specific reverse transcription primers. (32) The flRNA refers to HBV transcripts terminating at the canonical polyadenylation signal TATAAA, which is downstream of the HBx ORF. (29, 30, 32, (47) (48) (49) A trRNA species, identified by Hilger et al. in paired liver tumor tissue and peritumor tissues in 1991, terminates at a cryptic polyadenylation signal within the HBx ORF. (49) This signal, a CATAAA motif, is present in most HBV DNA integrants without the canonical polyadenylation signal, (47) which may be used to polyadenylate the surface mRNA or HBx mRNA transcribed from the integrated HBV DNA. Thus, whether the encapsulated, polyadenylated serum HBV RNA is equal to flRNA or contains such trRNA species awaits further investigation. Collectively, the data suggest that the species of serum HBV RNA are heterogeneous and the compositions of these RNA species may vary depending on different stages of chronic HBV infection, different antiviral treatments, and more importantly, detection methods with different primers (Figure 2 and Table 1 ). Therefore, considering that the molecular characteristics of serum HBV RNA have not been well defined and a standardized method for serum HBV RNA detection is unavailable, further basic research and assays, such as northern blot and single-molecule direct RNA sequencing, are needed. An improved understanding of the molecular biology of serum HBV RNA will aid the development of an accurate and reliable serum HBV RNA measurement method.
Correlation Between Serum HBV RNA and Other HBV Markers

CoRRelatIoN WItH SeRUM HBV DNa aND HepatItIS B e aNtIgeN
Theoretically, both serum HBV DNA and RNA can be useful markers for HBV cccDNA activity in treatment-naive patients. However, in CHB patients under NA therapy, HBV DNA is suppressed due to halted pgRNA reverse transcription, making RNA a more direct marker for cccDNA. Consistently, van Bommel et al. have demonstrated that the levels of both serum HBV flRNA and trRNA strongly correlate with serum HBV DNA before treatment, but the correlation becomes weaker upon receiving NAs (32) (Table 2) . For untreated patients, the correlation coefficient of serum HBV pgRNA and DNA is higher in hepatitis B e antigen (HBeAg)-negative patients than HBeAg-positive patients (r = 0.741 and r = 0.532, P < 0.001, respectively). (37) However, van Campenhout et al. reported a comparable correlation of serum HBV flRNA to DNA between HBeAg-positive and HBeAg-negative patients (r = 0.72 and r = 0.78, P < 0.001, respectively). (35) Such a discrepancy may be due to the differences in the number of subjects and/or patient characteristics. Moreover, the serum HBV RNA quantitation methods used in these two studies are different (Table 1) , which may have resulted in different quantification results as well as different correlations with serum HBV DNA. Thus, the correlation between serum HBV RNA and DNA in HBeAg-positive and HBeAg-negative patients with or without antiviral treatment is contingent on further investigations.
CoRRelatIoN WItH SeRUM HBsag aND HBcRag
HBsAg is a widely used serological marker for chronic HBV infection, which not only reflects intrahepatic HBV activity but predicts the efficacy of antiviral agents. (50) Thus far, only two studies have shown that serum HBV RNA levels of on-treatment patients strongly correlated with HBsAg titers with a correlation coefficient around 0.7, (21, 41) but other studies have reported a more moderate correlation with a correlation coefficient around 0.4 for pretreatment patients (32, 35, 37) (Table 3) . However, for HBeAgnegative patients, there is a weak or no correlation between serum HBV RNA and HBsAg. (20, 35, 37) One plausible explanation is that the serum HBsAg in HBeAg-negative patients is largely derived from the integrated HBV genome, rather than cccDNA. (15) In addition, HBcrAg, a mixture of HBcAg, HBeAg, and the less characterized p22cr, all of which are predominantly cccDNA-derived, has been advocated as a potential surrogate marker for cccDNA activity. (51) Rokuhara et al. reported that serum HBV RNA levels correlate well with serum HBcrAg in patients at the start of treatment (r = 0.841, P < 0.001) and during treatment (r = 0.777, P < 0.001). (36) However, more : r = 0.61 n/a n/a n/a 6th month: flRNA * : r = 0.53 n/a n/a n/a trRNA † : r = 0.62 n/a 52 n/a n/a C RNA ‡ : 3rd month: R 2 = 0.321 n/a 41 86 PreC/C RNA ‡ : HBeAg + : strongly n/a n/a n/a 20 HBeAg -: strongly n/a n/a n/a 
CoRRelatIoN WItH cccDNa aND otHeR VIRal MaRKeRS
NA therapy can reduce serum HBV DNA to an undetectable level but does not directly influence the production of HBsAg and HBcrAg or serum HBV RNA from cccDNA. In this regard, HBsAg, HBcrAg, and particularly the serum HBV RNA appear to be better surrogate markers for cccDNA than serum HBV DNA. Huang et al. reported that serum HBV pgRNA weakly correlated with cccDNA in untreated CHB patients with a correlation coefficient of 0.363 (P < 0.001), (37) which is similar to the result of Gao et al. (r = 0.25, P < 0.01), who quantified serum polyadenylated HBV RNA by RACE-quantitative PCR. (33) In a CHB natural history study, Wang et al. found a moderate overall correlation between serum 3.5-kb RNA and intrahepatic cccDNA (r = 0.596, P < 0.001) among all of the recruited patients; however, when classifying the patients into immune-tolerant, HBeAg-positive immune active, inactive carrier, and HBeAg-negative immune active phases, the correlation disappeared in all phases. (52) For patients under NA treatment, Wang et al. found no significant correlation between serum HBV RNA and cccDNA copy numbers. (21) In addition, Gao et al. reported that serum HBV polyA RNA had no correlation with intrahepatic cccDNA at 96 weeks after NA treatment. (33) Despite there being no correlation between cccDNA and serum HBV pgRNA, the latter strongly correlates with intrahepatic HBV pgRNA, as well as with the ratio of intrahepatic HBV pgRNA to cccDNA, which reflects intrahepatic viral transcription activity. (21) In addition to the intrahepatic viral replicative markers, serum HBV pgRNA correlated with liver injury or histopathology, (21, 52) which raises the question of whether the serum HBV RNA, or at least part of them, are released through hepatocyte destruction.
Thus, it can be concluded that the correlation between serum HBV RNA and intrahepatic cccDNA is not well justified and may differ between untreated and treated patients. Additionally, the correlation may vary based on different CHB stages and even different detection methods for serum HBV RNA and cccDNA. Therefore, the development of accurate and standardized protocols for serum HBV RNA and intrahepatic cccDNA quantitation is urgently needed to determine the correlation between serum HBV RNA and intrahepatic cccDNA. : r = 0.34 n/a n/a n/a 6th month: flRNA * : r = 0.36 n/a n/a n/a trRNA † : r = 0.31 n/a 52 n/a n/a C RNA ‡ : 3rd month: R 2 = 0.407 n/a 41 86 PreC/C RNA ‡ : HBeAg + : moderate n/a n/a n/a 20 HBeAg -: no correlation n/a n/a n/a 
Clinical Significance of Serum HBV RNA
SeRUM HBV RNa aND aNtIVIRal tReatMeNt eFFICaCy
A number of studies have inferred that serum HBV RNA can be a useful marker for monitoring the efficacy of antiviral therapy, such as NAs and interferon-alpha (IFN-α) . (20, 32, 34, 41) A study on 52 CHB patients receiving NA therapy revealed that low serum HBV RNA levels at week 12 of treatment can predict the initial virological response, which is defined as an interval from detectable to undetectable HBV DNA level <16 weeks. (41) However, the ability of serum HBV RNA to predict the long-term outcome of NA treatment remains unclear. Due to this fact, additional longitudinal studies are needed to assess the potential predictive role of serum HBV RNA in the virological response. If it holds up, "virological response" can be redefined by complementing the current criteria with serum HBV RNA. Another study of 50 HBeAg-positive CHB patients treated with NAs reported that serum HBV flRNA levels at baseline can predict HBeAg seroconversion with superior accuracy to that of HBV DNA levels (area under the receiver operating characteristic curve = 0.73 versus 0.67), and that the decline of serum HBV RNA also showed a better prediction of HBeAg seroconversion than HBV DNA and HBsAg during antiviral treatment. (32) This study indicates a quite good predictive value of serum HBV RNA for HBeAg seroconversion, which should be further validated in future studies with a large sample size of HBeAg-seroconverted patients.
The effect of NA and IFN-α treatments on serum HBV RNA is different. (53) Mechanistically, while NAs specifically block the reverse transcription of encapsidated HBV pgRNA to DNA, the pleiotropic IFN-α can induce cccDNA degradation and inhibit cccDNA transcription, (54) promote the decay of HBV pgRNA by IFN-stimulated ribonucleases, (55) and prevent pgRNA encapsidation. (56) Therefore, when compared to NA treatment, IFN-α treatment is expected to achieve a stronger decline of serum HBV RNA. Van Bommel et al. reported that there was a greater reduction of serum HBV RNA in patients receiving peg-IFN + lamivudine combination therapy compared to those receiving peg-IFN monotherapy (P < 0.05). (34) However, to the best of our knowledge, no research has been performed to compare the kinetics of serum HBV RNA decline between NA monotherapy and IFN-α monotherapy. In addition, Jansen et al. found a more pronounced decline of HBV RNA load at week 30 in responders to peg-IFN and adefovir combination therapy than nonresponders (P = 0.01). (20) Regarding patients under peg-IFN therapy, van Bommel et al. reported that the cutoff of serum HBV RNA at 5.5-log 10 copies/mL at week 12 can identify a higher proportion of nonresponders (30%) than the HBV DNA cutoff of 8.9-log 10 IU/mL (22%) or the HBeAg cutoff of 2.7-log 10 IU/mL (29%). However, the HBsAg cutoff of 2.8-log 10 IU/mL could identify the largest proportion (41%) of nonresponders. (34) All of these studies indicate that serum HBV RNA may serve as an additional biomarker for monitoring the efficacy of antiviral therapy. However, it remains unclear whether serum HBV RNA is better than current biomarkers or whether it can replace other markers for such clinical applications.
SeRUM HBV RNa aND VIRal ReBoUND aFteR tReatMeNt CeSSatIoN
Currently, for HBeAg-positive patients being treated with NAs, treatment discontinuation can be considered after at least 1 year of consolidation therapy if patients achieve undetectable HBV DNA, alanine aminotransferase (ALT) normalization and HBeAg seroconversion. (57) Despite these criteria, virological relapse is common after treatment cessation. Therefore, a better biomarker(s) for predicting safe withdrawal of NA treatment in CHB patients is needed. As serum HBV RNA is considered to be a potential biomarker for cccDNA activity, the loss of serum HBV RNA may reflect the transcription silencing of cccDNA and may be an indicator for safe withdrawal of antiviral treatment. (58, 59) In line with this notion, a study of 36 patients treated with NAs showed that, after 3 months of treatment, serum HBV DNA+RNA titers were tightly associated with HBV DNA rebound (P = 0.043; odds ratio [OR], 9.474, 95% confidence interval [CI], 1.069-83.957) and ALT relapse (P = 0.050; OR, 8.032, 95% CI, 0.997-64.683). (40) However, the criteria for discontinuing NA therapy in this study were not uniform. Another cohort study on 33 CHB patients withdrawing NAs revealed that viral rebound occurred in all patients who were HBV RNA-positive at the end of treatment but in only 25% of patients who were HBV RNA-negative. (6) Theoretically, the most promising area for clinical application of serum HBV RNA is the prediction of relapse and sustained response, especially HBsAg loss after treatment discontinuation. However, additional studies with larger sample sizes are required to further evaluate the role of HBV RNA in predicting HBV relapse and sustained response after discontinuation of NA treatment.
Future Research on Serum HBV RNA
Before a widespread clinical application of serum HBV RNA for CHB can be accepted and applied, certain fundamental questions need to be answered.
(1) Basic and clinical studies are needed to further delineate the composition and molecular details of serum HBV RNA under different situations, such as different stages of CHB natural history, from baseline to different treatment time points, receiving NA therapy or IFN therapy, as well as other new therapies for CHB. It is also essential to understand how the serum HBV RNA, specifically pgRNA, is released from hepatocytes. Is it in the virion or a naked capsid? Is the egress mechanism different between HBV DNA-containing particles and RNA-containing particles? (2) The methodology for detecting and quantifying serum HBV RNA, which may be related to the RNA species, as well as the intrahepatic cccDNA quantification, should be standardized to make the results of different studies comparable. Due to the potential high complexity of serum HBV RNA, an ideal PCR method would be expected to detect all possible serum HBV RNA species discussed in this review. (3) After characterizing serum HBV RNA species and perfecting the method for detection, their correlations with the clinical outcomes of CHB patients (including response to antiviral therapy especially HBsAg loss and hepatitis flare after withdrawal of NAs), need further investigation as different species of serum HBV RNA may have different clinical implications. (4) The general applicability of serum HBV RNA among CHB patients of different ethnic groups and genotypes should be studied, and a pan-genotypic serum HBV RNA detection is warranted. (5) Circulating HBV RNA may be a marker for hepatocarcinogenesis. (47, 49) Furthermore, a recent study demonstrated that pgRNA in liver tumor tissue correlated with the absence of tumorous microvascular invasion and better patient survival. (60) Hence, the association and correlation of serum HBV RNA with HCC development also deserve exploration.
Conclusion
In summary, serum HBV RNA possesses potential as a marker for chronic HBV infection. Growing evidence supports serum HBV RNA correlations with serum HBsAg and HBcrAg and with HBV DNA before treatment. Serum HBV RNA may serve as a better surrogate marker for cccDNA activity in virally suppressed patients receiving NA therapy. Although the methodologies of detection varied from study to study, serum HBV RNA has shown preliminary clinical significance. Therefore, we envisage that extensive research will be conducted to further characterize the molecular biology of serum HBV RNA and assess its clinical potential.
